Lexeo Therapeutics Files 8-K
Ticker: LXEO · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, corporate-events
Related Tickers: LXEO
TL;DR
Lexeo Therapeutics filed an 8-K on Oct 7, 2025, covering disclosures and financial updates.
AI Summary
Lexeo Therapeutics, Inc. filed an 8-K on October 7, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company's principal executive offices are located at 345 Park Avenue South, Floor 6, New York, NY 10010.
Why It Matters
This 8-K filing provides an update on Lexeo Therapeutics' corporate activities and disclosures, which is important for investors to stay informed about the company's regulatory compliance and operational events.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative or positive news that would immediately impact the company's risk profile.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- October 07, 2025 (date) — Date of earliest event reported
- 345 Park Avenue South, Floor 6 (location) — Principal Executive Offices
- New York, New York (location) — Principal Executive Offices City and State
- 10010 (location) — Principal Executive Offices Zip Code
FAQ
What is the primary purpose of this 8-K filing for Lexeo Therapeutics?
The primary purpose is to report on various events including Regulation FD disclosures, other events, and financial statements and exhibits, as of October 7, 2025.
When was the earliest event reported in this filing?
The earliest event reported was on October 7, 2025.
What is Lexeo Therapeutics' principal executive office address?
Lexeo Therapeutics' principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York, 10010.
What is the Commission File Number for Lexeo Therapeutics?
The Commission File Number for Lexeo Therapeutics is 001-41855.
What is the IRS Employer Identification Number for Lexeo Therapeutics?
The IRS Employer Identification Number for Lexeo Therapeutics is 85-4012572.
Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-10-07 06:03:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo
Filing Documents
- lxeo-20251007.htm (8-K) — 52KB
- lxeo-ex99_1.htm (EX-99.1) — 29KB
- lxeo-ex99_2.htm (EX-99.2) — 41KB
- img47863792_0.jpg (GRAPHIC) — 243KB
- lxeo-ex99_1s1.jpg (GRAPHIC) — 290KB
- lxeo-ex99_1s2.jpg (GRAPHIC) — 526KB
- lxeo-ex99_1s3.jpg (GRAPHIC) — 505KB
- lxeo-ex99_1s4.jpg (GRAPHIC) — 352KB
- lxeo-ex99_1s5.jpg (GRAPHIC) — 487KB
- lxeo-ex99_1s6.jpg (GRAPHIC) — 345KB
- lxeo-ex99_1s7.jpg (GRAPHIC) — 424KB
- lxeo-ex99_1s8.jpg (GRAPHIC) — 443KB
- lxeo-ex99_1s9.jpg (GRAPHIC) — 466KB
- lxeo-ex99_1s10.jpg (GRAPHIC) — 225KB
- lxeo-ex99_1s11.jpg (GRAPHIC) — 403KB
- lxeo-ex99_1s12.jpg (GRAPHIC) — 327KB
- lxeo-ex99_1s13.jpg (GRAPHIC) — 312KB
- lxeo-ex99_1s14.jpg (GRAPHIC) — 424KB
- lxeo-ex99_1s15.jpg (GRAPHIC) — 334KB
- lxeo-ex99_1s16.jpg (GRAPHIC) — 369KB
- lxeo-ex99_1s17.jpg (GRAPHIC) — 323KB
- lxeo-ex99_1s18.jpg (GRAPHIC) — 377KB
- lxeo-ex99_1s19.jpg (GRAPHIC) — 311KB
- lxeo-ex99_1s20.jpg (GRAPHIC) — 336KB
- lxeo-ex99_1s21.jpg (GRAPHIC) — 179KB
- 0001193125-25-232514.txt ( ) — 11267KB
- lxeo-20251007.xsd (EX-101.SCH) — 25KB
- lxeo-20251007_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The corporate presentation to be used in connection with the webcast described in Item 8.01 below is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events. On October 7, 2025, Lexeo Therapeutics, Inc. (the " Company ") issued a press release announcing regulatory updates to key components of an accelerated approval pathway for LX2006 for the treatment of Friedreich ataxia (" FA ") cardiomyopathy based on FDA feedback to date, alongside positive interim Phase 1/2 clinical data for LX2006 for the treatment of FA cardiomyopathy. As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on October 7, 2025 to discuss regulatory updates and interim Phase 1/2 clinical data of LX2006 for the treatment of FA cardiomyopathy. The press release is attached hereto as Exhibit 99.2 and incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Corporate Presentation, October 7, 2025, furnished herewith. 99.2 Press release issued by the Company on October 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: October 7, 2025 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer